FDA Revives Wellcovorin Tablets for Patient Use
Published Date: 9/24/2025
Notice
Summary
The FDA just gave the green light again to Wellcovorin tablets, a medicine that helps patients during certain cancer treatments. This approval affects doctors, patients, and drug makers by bringing this important drug back to the market. Expect Wellcovorin to be available soon, helping folks without extra cost surprises.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Wellcovorin NDA Approval Restored
The FDA approved the previously withdrawn new drug application (NDA) for Wellcovorin (leucovorin calcium) tablets in strengths equivalent to 5 mg base and 25 mg base. The Agency says it initiated this action on the basis of new data and published this notice; the approval returns the drug to the market and affects doctors, patients, and drug makers.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20503, Determination That Oxandrin (Oxandrolone) Tablets, 2.5 Milligrams and 10 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness; Correction
The FDA fixed a previous announcement about Oxandrin tablets (2.5 mg and 10 mg) being pulled from the market due to safety or effectiveness concerns. This update confirms that not only the original drug but also several generic versions were withdrawn and removed from the official drug list. Patients, doctors, and drug makers should note these changes, which affect availability and prescribing options immediately.
Previous / Next Documents
Previous: 2025-18509, Submission for OMB Review; Comment Request
The Department of Agriculture wants your thoughts on a new info collection about keeping agricultural data safe. If you work with or rely on this data, your feedback by October 24, 2025, can help shape how the government protects it without making things harder for you. No big costs are expected, but they want to make sure the process is clear and easy for everyone involved.
Next: 2025-18511, Information Collections Being Submitted for Review and Approval to Office of Management and Budget
The FCC is asking everyone, especially small businesses with fewer than 25 employees, to share ideas on how to make paperwork easier and less time-consuming. They want to make sure all info collections have proper approval and no one gets penalized unfairly. This is a chance to help cut red tape and improve how the FCC collects info, with deadlines coming soon.